Perspectives

How does this study impact clinical practice?

• Escalation from dulaglutide 1.5 mg to dulaglutide 3 mg or 4.5 mg provided clinically relevant, dose-related improvements in glycemic control and body weight with an acceptable safety profile.
• Results at 52-weeks were consistent with the 36-week results and further details will be disclosed at a later date.
• The AWARD-11 results have been submitted to regulatory authorities in the U.S. and Europe for review.